Company logo

AXSM - Axsome Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
New York, United States

AXSM price evolution
AXSM
Balance Sheet
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $141.22 $164.66 $183.88 $202.36
Short term investments
Net receivables
Inventory
Total current assets $141.65 $165.04 $184.02 $203.27
Long term investments
Property, plant & equipment $1.29 $1.55 $1.79 $0.04
Goodwill & intangible assets
Total noncurrent assets $1.61 $1.87 $2.11 $0.36
Total investments
Total assets $143.26 $166.9 $186.13 $203.63
Current liabilities
Accounts payable $11.61 $14.62 $13.5 $11.32
Deferred revenue
Short long term debt $1.09 $1.2 $1.22
Total current liabilities $22.86 $21.68 $23.44 $20.34
Long term debt $48.96 $48.93 $48.9 $48.03
Total noncurrent liabilities $48.96 $48.93 $48.9 $48.03
Total debt $50.05 $50.12 $50.12 $48.03
Total liabilities $71.83 $70.61 $72.34 $68.37
Shareholders' equity
Retained earnings -$340.34 -$308.06 -$278.8 -$249.63
Other shareholder equity
Total shareholder equity $71.44 $96.29 $113.79 $135.26
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $183.88 $219.97 $13.97 $34.02
Short term investments
Net receivables
Inventory
Total current assets $184.02 $220.38 $15.22 $35.3
Long term investments
Property, plant & equipment $1.79 $0.03 $0.05 $0.07
Goodwill & intangible assets
Total noncurrent assets $2.11 $0.17 $0.16 $0.26
Total investments
Total assets $186.13 $220.55 $15.38 $35.56
Current liabilities
Accounts payable $13.5 $10.94 $3.69 $3.44
Deferred revenue
Short long term debt $1.22 $2.6 $3.29 $3.27
Total current liabilities $23.44 $24.49 $10.82 $12.18
Long term debt $48.9 $17.33 $3.62 $6.66
Total noncurrent liabilities $48.9 $17.33 $3.62 $6.66
Total debt $50.12 $19.93 $6.91 $9.93
Total liabilities $72.34 $41.83 $14.44 $18.84
Shareholders' equity
Retained earnings -$278.8 -$175.9 -$107.55 -$76.58
Other shareholder equity $0
Total shareholder equity $113.79 $178.72 $0.94 $16.72
Income Statement
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $14.5 $16.6 $17.38 $14.8
Selling, general & administrative $16.34 $11.25 $10.36 $6.33
Total operating expenses $30.85 $27.84 $27.74 $21.13
Operating income -$30.85 -$27.84 -$27.74 -$21.13
Income from continuing operations
EBIT -$30.85 -$27.84 -$27.74 -$22.37
Income tax expense -$0.05
Interest expense $1.44 $1.42 $1.47 $0.55
Net income
Net income -$32.28 -$29.26 -$29.16 -$22.92
Income (for common shares) -$32.28 -$29.26 -$29.16 -$22.92
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $70.24 $53.65 $23.5 $19.96
Selling, general & administrative $28.9 $13.6 $9.35 $7.21
Total operating expenses $99.14 $67.25 $32.85 $27.16
Operating income -$99.14 -$67.25 -$32.85 -$27.16
Income from continuing operations
EBIT -$100.39 -$67.25 -$30.06 -$27.81
Income tax expense -$0.05 -$0.14 -$0.22 -$0.21
Interest expense $2.57 $1.24 $1.13 $1.34
Net income
Net income -$102.9 -$68.35 -$30.97 -$28.94
Income (for common shares) -$102.9 -$68.35 -$30.97 -$28.94
Cash Flow
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income -$32.28 -$29.26 -$29.16 -$22.92
Operating activities
Depreciation $0.28 $0.27 $0.06 $0.01
Business acquisitions & disposals
Stock-based compensation $5.46 $3.73 $5.61 $2.87
Total cash flows from operations -$25.39 -$27.22 -$20.55 -$15.73
Investing activities
Capital expenditures -$0.02 -$0.03 -$0.02 -$0.01
Investments
Total cash flows from investing -$0.02 -$0.03 -$0.02 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $2.06 $8.03 $2.09 $0.19
Net borrowings $27.24
Total cash flows from financing $1.97 $8.03 $2.09 $27.43
Effect of exchange rate
Change in cash and equivalents -$23.44 -$19.22 -$18.48 $11.68
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income -$102.9 -$68.35 -$30.97 -$28.94
Operating activities
Depreciation $0.08 $0.04 $0.05 $0.04
Business acquisitions & disposals
Stock-based compensation $14.76 $6.12 $1.75 $2.07
Total cash flows from operations -$78.46 -$46.38 -$30.05 -$26.47
Investing activities
Capital expenditures -$0.05 -$0.02 -$0.03 -$0.01
Investments
Total cash flows from investing -$0.05 -$0.02 -$0.03 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $15.18 $239.63 $13.39 $24.16
Net borrowings $27.24 $12.76 -$3.36 -$0.28
Total cash flows from financing $42.41 $252.39 $10.03 $23.88
Effect of exchange rate
Change in cash and equivalents -$36.09 $206 -$20.05 -$2.6
Fundamentals
Market cap $1.53B
Enterprise value $1.44B
Shares outstanding 37.68M
Revenue $0.00
EBITDA -$108.19M
EBIT -$108.81M
Net Income -$113.63M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -13.47
EV/Sales N/A
EV/EBITDA -13.30
EV/EBIT -13.23
P/S ratio N/A
P/B ratio 21.43
Book/Share 1.90
Cash/Share 3.75
EPS -$3.02
ROA -64.94%
ROE -109.06%
Debt/Equity 0.64
Net debt/EBITDA 0.64
Current ratio 6.20
Quick ratio 6.20